RXRX Stock Outlook 2026: AI Drug Discovery's Bold Promise vs. the Cash-Burn Clock
RXRX (Recursion Pharmaceuticals) 2026 stock outlook. A qualitative deep dive into the AI drug discovery platform Recursion OS, the BioHive supercomputer, Nvidia's investment and exascale compute, the clinical pipeline, big-pharma partnerships, heavy cash burn, the Exscientia merger, and dilution risk.
RXRX Recursion Pharmaceuticals AI drug discovery